Abbott’s HeartMate 3 extends life by 5 years for advanced heart failure patients

Abbott’s HeartMate 3 extends life by 5 years for advanced heart failure patients

Source: 
MedCity News
snippet: 

It is the first LVAD trial to examine five-year outcomes and surpasses a previous Abbott study on HeartMate 3, which recorded a survival time of two years. The device was found to reduce morbidity and mortality, largely because of fewer deaths by stroke, clotting and bleeding.